<DOC>
	<DOCNO>NCT01599923</DOCNO>
	<brief_summary>There FDA approve therapy treatment scorpion envenomation United States . Centruroides scorpion envenomation produce pattern neurotoxicity spectrum severity range trivial life threaten . Patients stung Centruroides scorpion develop clinical syndrome may require sedation benzodiazepine observation 6 28 hour intensive care monitoring . A safe therapy necessary halt progression symptom early clinical course avoid clinical deterioration occur en route tertiary facility . Alacramyn® anticipate safer effective present standard care United States , midazolam , faster-acting thus eliminate need transport rural patient reduce hospitalization time .</brief_summary>
	<brief_title>Open Label Study Alacramyn® Pediatric Patients With Scorpion Sting Envenomation</brief_title>
	<detailed_description>The purpose open label , confirmatory , control clinical trial Mexico provide additional data safety efficacy Alacramyn® treatment patient envenom scorpion sting . This study take place Morelos Children 's Hospital Cuernavaca , Mexico . Patients arrive emergency department present scorpion sting symptom evaluate treatment respect inclusion/exclusion criterion accord study procedure . Only patient clinically important systemic sign scorpion sting envenomation include study . Baseline measure include severity evaluation scorpion sting envenomation . The patient 's vital sign , concomitant medication , medical history demographic data collect . Blood test do haematology , chemistry , venom anti-venom level urine test . After informed consent inclusion/exclusion criterion obtain verify , baseline measurement complete , three vial Alacramyn® administer . At one hour assessment additional vial Alacramyn® administer important systemic sign scorpion envenomation present . The assessment repeat two hour final vial Alacramyn® administer deem necessary . Patient discharge 4 hour assessment symptom resolve . Prior discharge repeat lab work , physical assessment , vital sign do . Those remain extended care underwent final study assessment time hospital discharge 24 hour study drug infusion hospitalization continue . All patient participate study contact 7 14 day treatment , look symptom suggestive ongoing venom effect , delay serum sickness , well adverse event report patient .</detailed_description>
	<mesh_term>Bites Stings</mesh_term>
	<mesh_term>Poisoning</mesh_term>
	<mesh_term>Scorpion Stings</mesh_term>
	<mesh_term>Antivenins</mesh_term>
	<criteria>Males females 6 month 18 year age Presenting emergency care within 5 hour clinically important sign scorpion sting envenomation Signed write Informed Consent parent legal guardian No participation clinical drug trial within last month concomitantly Allergy horse serum Use within past 24 hour drug expect alter immune response Use antivenom within last month concomitantly Underlying medical condition significantly alter immune response Concurrent medical condition involve baseline neurological status mimic envenomation Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>scorpion</keyword>
	<keyword>envenomation</keyword>
	<keyword>Alacramyn</keyword>
</DOC>